USFDA Approves Strides Pharma's Generic Fluoxetine Tablets for Enhanced Dosing Flexibility
Monday, 16 September 2024, 03:05
USFDA Approval for Strides Pharma
Strides Pharma Science Ltd's subsidiary has achieved a significant milestone with the USFDA approval of its generic Fluoxetine tablets (60 mg). These tablets are designed to be equivalent to TWi Pharmaceuticals' version, ensuring competitive presence in the antidepressant market.
Details of the Approval
- Product: Generic Fluoxetine Tablets
- Strength: 60 mg
- Production Facility: Puducherry
- Market Impact: Enhanced competition in the fluoxetine sector
Implications for Patients
The launch of this generic medication is poised to provide greater dosing flexibility for patients relying on antidepressants, aligning with IMS data trends observed in antidepressant usage.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.